vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$75.5M vs $69.8M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 31.3%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
PBYI vs RIGL — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$69.8M
营收增速更快
PBYI
高出6.5%
21.2%
两年增速更快
RIGL
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 69.3% | 91.5% |
| 营业利润率 | 22.7% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | 27.7% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $0.26 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIRIGL
| Q4 25 | $75.5M | $69.8M | ||
| Q3 25 | $54.5M | $69.5M | ||
| Q2 25 | $52.4M | $101.7M | ||
| Q1 25 | $46.0M | $53.3M | ||
| Q4 24 | $59.1M | $57.6M | ||
| Q3 24 | $80.5M | $55.3M | ||
| Q2 24 | $47.1M | $36.8M | ||
| Q1 24 | $43.8M | $29.5M |
净利润PBYIRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $8.8M | $27.9M | ||
| Q2 25 | $5.9M | $59.6M | ||
| Q1 25 | $3.0M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $20.3M | $12.4M | ||
| Q2 24 | $-4.5M | $-1.0M | ||
| Q1 24 | $-4.8M | $-8.2M |
毛利率PBYIRIGL
| Q4 25 | 69.3% | 91.5% | ||
| Q3 25 | 77.7% | 93.2% | ||
| Q2 25 | 76.5% | 95.6% | ||
| Q1 25 | 77.1% | 91.7% | ||
| Q4 24 | 76.4% | 89.9% | ||
| Q3 24 | 63.9% | 85.5% | ||
| Q2 24 | 77.4% | 92.4% | ||
| Q1 24 | 75.5% | 93.1% |
营业利润率PBYIRIGL
| Q4 25 | 22.7% | 33.2% | ||
| Q3 25 | 17.6% | 40.9% | ||
| Q2 25 | 12.7% | 60.1% | ||
| Q1 25 | 8.7% | 23.9% | ||
| Q4 24 | 22.6% | 28.9% | ||
| Q3 24 | 27.4% | 25.4% | ||
| Q2 24 | -4.6% | 1.2% | ||
| Q1 24 | -5.3% | -23.6% |
净利率PBYIRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 16.2% | 40.2% | ||
| Q2 25 | 11.2% | 58.6% | ||
| Q1 25 | 6.5% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 25.2% | 22.5% | ||
| Q2 24 | -9.6% | -2.8% | ||
| Q1 24 | -11.0% | -27.9% |
每股收益（稀释后）PBYIRIGL
| Q4 25 | $0.26 | $14.11 | ||
| Q3 25 | $0.17 | $1.46 | ||
| Q2 25 | $0.12 | $3.28 | ||
| Q1 25 | $0.06 | $0.63 | ||
| Q4 24 | $0.40 | $0.82 | ||
| Q3 24 | $0.41 | $0.70 | ||
| Q2 24 | $-0.09 | $-0.06 | ||
| Q1 24 | $-0.10 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $155.0M |
| 总债务越低越好 | $22.7M | $52.5M |
| 股东权益账面价值 | $130.3M | $391.5M |
| 总资产 | $216.3M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资PBYIRIGL
| Q4 25 | $97.5M | $155.0M | ||
| Q3 25 | $94.4M | $137.1M | ||
| Q2 25 | $96.0M | $108.4M | ||
| Q1 25 | $93.2M | $77.1M | ||
| Q4 24 | $101.0M | $77.3M | ||
| Q3 24 | $96.7M | $61.1M | ||
| Q2 24 | $96.8M | $49.1M | ||
| Q1 24 | $107.2M | $49.5M |
总债务PBYIRIGL
| Q4 25 | $22.7M | $52.5M | ||
| Q3 25 | $34.0M | $60.0M | ||
| Q2 25 | $45.3M | $60.0M | ||
| Q1 25 | $56.7M | $60.0M | ||
| Q4 24 | $68.0M | $60.0M | ||
| Q3 24 | $79.3M | $60.0M | ||
| Q2 24 | $90.7M | $60.0M | ||
| Q1 24 | $102.0M | $60.0M |
股东权益PBYIRIGL
| Q4 25 | $130.3M | $391.5M | ||
| Q3 25 | $115.3M | $117.6M | ||
| Q2 25 | $104.7M | $81.9M | ||
| Q1 25 | $97.1M | $18.6M | ||
| Q4 24 | $92.1M | $3.3M | ||
| Q3 24 | $71.1M | $-14.6M | ||
| Q2 24 | $48.5M | $-29.9M | ||
| Q1 24 | $51.0M | $-31.7M |
总资产PBYIRIGL
| Q4 25 | $216.3M | $513.6M | ||
| Q3 25 | $202.9M | $242.5M | ||
| Q2 25 | $194.9M | $206.7M | ||
| Q1 25 | $196.2M | $176.0M | ||
| Q4 24 | $213.3M | $164.0M | ||
| Q3 24 | $220.7M | $139.4M | ||
| Q2 24 | $205.0M | $128.4M | ||
| Q1 24 | $214.1M | $126.5M |
负债/权益比PBYIRIGL
| Q4 25 | 0.17× | 0.13× | ||
| Q3 25 | 0.30× | 0.51× | ||
| Q2 25 | 0.43× | 0.73× | ||
| Q1 25 | 0.58× | 3.23× | ||
| Q4 24 | 0.74× | 18.25× | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIRIGL
| Q4 25 | $14.4M | $22.0M | ||
| Q3 25 | $9.7M | $24.0M | ||
| Q2 25 | $14.1M | $30.5M | ||
| Q1 25 | $3.6M | $-893.0K | ||
| Q4 24 | $15.6M | $14.5M | ||
| Q3 24 | $11.0M | $21.7M | ||
| Q2 24 | $1.0M | $302.0K | ||
| Q1 24 | $11.2M | $-5.0M |
自由现金流PBYIRIGL
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYIRIGL
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYIRIGL
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYIRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 1.10× | 0.86× | ||
| Q2 25 | 2.41× | 0.51× | ||
| Q1 25 | 1.21× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 0.54× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
